Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study (1998)
    Springer
    Journal of cancer research and clinical oncology 124 (1998), S. 627-632 
    Details
    ISSN: 1432-1335
    Keywords: Key words Bendamustine ; Breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to determine the objective response rates and make further observations on the toxicity of this drug. A group of 37 patients, pretreated with chemotherapy for advanced disease, entered the trial. Treatment consisted of 150 mg/m2 bendamustine on days 1 and 2 of a 4-week treatment course. Patients continued to receive treatment until complete remission and then two further courses, until tumour progression or unacceptable toxicity ensued. A total of 36 patients received at least one treatment course and were assessable for toxicity; 33 patients were evaluable for treatment results. Dose-limiting grade 3 and 4 WHO toxicity occurred in 5 and 3 patients respectively; 27% of patients entered complete or partial tumour remission. The median time to tumour progression was 2 months with a range of 1–14 months. The efficacy of bendamustine was apparently independent of pretreatment with anthracyclines, suggesting a lack of cross-resistance between bendamustine and anthracyclines. It can be concluded that bendamustine in the dose and application schedule used here is active in the salvage therapy of women with advanced breast cancer. The toxicity was acceptable. Future studies have to confirm the data of this pilot trial and to define the role of bendamustine in the combination chemotherapy of metastatic breast cancer that has been suggested by previous trials.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004320050225
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies (1998)
    Springer
    Journal of cancer research and clinical oncology 124 (1998), S. 288-290 
    Details
    ISSN: 1432-1335
    Keywords: Keywords Pharmacoeconomics ; High-dose chemotherapy ; Peripheral blood stem cell support
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Discussion of the total costs and cost-effectiveness ratios of patients receiving high-dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) is controversial. In Germany, no reliable data are available, whereas in other countries this issue has been extensively studied. We performed a pharmacoeconomic evaluation on all patients (n = 37) treated with HDC and PBSCS at our institution between July 1994 and June 1997. Patients suffered from high-risk or poor-prognosis breast cancer (n = 24), Hodgkin's disease (n = 3), high-grade non-Hodgkin's lymphoma (n = 4), multiple myeloma (n = 2), small-cell cervical cancer (n = 1), malignant hystiocytosis (n = 1) and testicular cancer (n = 2). For pharmacoeconomic evaluation, the period from initiation of induction chemotherapy (IC) until reconstitution after the last course of HDC and PBSCS was considered. A total of 18 patients received IC/HDC/PBSCS for locally advanced or systemic disease, and 19 patients received adjuvant or consolidation IC/HDC/PBSCS. Treatment protocols were heterogeneous. Patients were treated with two to five courses (median two) respectively of IC and sequential mono-HDC (n = 26), tandem-HDC (n = 10) or triple-HDC (n = 1). All patients received granulocyte/macrophage-colony-stimulating factor (G-CSF) for stem cell mobilisation and for amelioration of neutropenia after HDC. The relative costs (based on supplier prices) for the total amount of drugs prescribed during the in-patient period was 29.8% for G-CSF, 35.8% for blood products 18.5% for chemotherapy, 2.4% for antiemetics, 5.9% for antimicrobial drugs and 7.6% for other drugs. Contrary to expectations, antimicrobial drugs had only a minor pharmacoeconomic impact during IC/HDC/PBSCS in patients with high-risk or poor-prognosis malignancies, indicating that prolonged septic complications were uncommon in our institution. We conclude that pharmacoeconomic evaluations in IC/HDC/PBSCS might be integrated into the effort to ensure quality control and monitoring.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004320050170
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells (1998)
    Springer
    Journal of cancer research and clinical oncology 124 (1998), S. 341-345 
    Details
    ISSN: 1432-1335
    Keywords: Key words Mobilization ; Chemotherapy ; Correlating CFU-GM and CD34+ cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We examined the efficiency of disease-specific “standard” chemotherapies epirubicin, cyclophosphamide (EC); cyclophosphamide, vincristine, doxorubicin, etoposide, prednisolone (CHOEP); epirubicin, ifosfamide (EPI/IFOS) for peripheral blood progenitor cell (PBPC) mobilization in comparison to well-characterized mobilization protocols, i.e. etoposide, ifosfamide, cisplatin, epirubicin (VIPE) and dexamethasone, carmustine, etoposide, cytarabine, melphalan (DexaBEAM). Twenty-seven patients with various malignancies underwent 75 apheresis procedures for PBPC collection. Median cell yields from all 75 aphereses were 1.18 × 105 mononuclear cells/kg [range (0.28–3.7) × 108], 1.4 × 105 granulocyte/macrophage-colony-forming units (CFU-GM)/kg [range (0.2–11) × 105] and 3.3 × 106 CD34+cells/kg [range (0.35–17.7) × 106. CD34+/CD90+ cells could be mobilized by all mobilization regimens used. The difference observed in the mobilization of CD34+ cells was only of low significance when the mobilization regimens were compared, whereas the mobilizations of MNC and CFU-GM were significantly different between the groups. Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P = 0.0005). Mobilized CD34+ PBPC were correlated with CFU-GM in all apheresis products. The linear correlation coefficients differed for the various mobilization groups: DexaBEAM (r=0.9, P 〈 0.0001), VIPE (r = 0.68, P = 0.0024), CHOEP (r = 0.52, P = 0.022), EPI/IFOS (r=0.34, P=0.11) and EC (r=0.23, P=0.2). We conclude that clonogenic assays can provide additional information about the autotransplant quality, particularly when alternative or new mobilization regimens are being investigated.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004320050180
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    A phase II study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric carcinoma (1998)
    Springer
    Journal of cancer research and clinical oncology 124 (1998), S. 335-340 
    Details
    ISSN: 1432-1335
    Keywords: Key words Gastric carcinoma ; High-dose 5-FU ; Leucovorin ; Doxorubicin ; Cisplatin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract On the basis of recent clinical data suggesting that high-dose continuous 5-fluorouracil (5-FU) is able to overcome resistance to 5-FU bolus application in gastric carcinoma, a phase II study was performed to evaluate the activity and toxicity of weekly high-dose 5-FU and leucovorin plus biweekly alternating doxorubicin and cisplatin as the first-line treatment in patients with advanced gastric carcinoma. Between October 1995 and September 1997, 24 consecutive patients with locally advanced (n = 4) or metastatic (n = 20) gastric carcinomas were treated with a combination of 500 mg/m2 leucovorin as a 2-h infusion, followed by 2.0 g/m2 5-FU as a 24-h continuous infusion once weekly for 6 weeks, plus 20 mg/m2 doxorubicin as a bolus application and 50 mg/m2 cisplatin as a 1-h infusion, week 1, 3 and 5 (FLAP regimen). Response, toxicity and survival data were evaluated. A total of 20 patients were evaluable for response and 24 for toxicity. Objective responses were observed in 11 patients (55%) with no complete remission. Four patients (20%) showed stabilization and 5 patients (25%) experienced progressive disease. The median time to disease progression was 8 months and the overall duration of survival was 14 months. Myelosuppression was significant. In 2 patients, grade 4 WHO thrombocytopenia and leukopenia/anaemia respectively were registered, but there were no treatment-related deaths. We conclude that the weekly alternating FLAP regimen is effective in advanced gastric carcinoma with tolerable toxicity. However, significant myelotoxicity and frequent hospitalization suggest that FLAP should not be preferred to other regimens used in metastatic disease. Currently we intend to establish this regimen in the neoadjuvant setting in patients with primary unresectable localized gastric carcinomas.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004320050179
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Ektope ACTH-Produktion und Cushing-Syndrom bei einem Patienten mit neuroendokrinem Thymuskarzinom (1996)
    Springer
    Der Onkologe 2 (1996), S. 491-493 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050072
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Harnblasenkarzinom: Fortschritt vorprogrammiert (1997)
    Springer
    Der Onkologe 3 (1997), S. 213-214 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050114
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Amifostin (1997)
    Springer
    Der Onkologe 3 (1997), S. 191-198 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050113
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Nachsorge beim Mammakarzinom (1998)
    Springer
    Der Onkologe 4 (1998), S. 954-958 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Die Nachsorge von Patientinnen mit Mammakarzinomen muß differenziert durchgeführt werden. Der Untersuchungsumfang muß sich danach ausrichten, welcher Nutzen für die Patientin aus den Untersuchungen abgeleitet werden kann. Unreflektierten Nachsorgeschemata werden damit deutliche Grenzen gesetzt, die es aus ärztlich-wissenschaftlichen, psychologischen und ökonomischen Gründen zu berücksichtigen gilt.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050282
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Antagonisierung von Wachstumsfaktor-Rezeptoren bei malignen Erkrankungen (1998)
    Springer
    Der Onkologe 4 (1998), S. 1054-1064 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Voraussetzung für ein geordnetes Wachstum und die Differenzierung von Geweben und Organen ist die interzelluläre Kommunikation. Eine wesentliche Rolle spielen dabei Wachstumsfaktoren, die ihre Effekte an Zielzellen über die Bindung und Aktivierung spezifischer Oberflächen-Rezeptoren entfalten. Eine Gruppe von Wachstumsfaktor-Rezeptoren besitzt intrinsische Aktivität als Protein-Tyrosinkinasen (PTK) im intrazellulären Teil des Moleküls, welche durch Ligandenbindung aktiviert wird. Die Stimulation der Rezeptoren löst eine Kaskade von intrazellulären Ereignissen aus, die in den letzten Jahren weitgehend entschlüsselt werden konnte, so daß die Grundlagen für eine klinische Anwendung von Modulatoren der PTK-Aktivität in der Tumortherapie erarbeitet sind. Die verschiedenen Elementarschritte der Signalübermittelung von der Plasmamembran bis zum Zellkern bieten dabei unterschiedliche Angriffspunkte für Inhibitionsstrategien. Diese umfassen eine Blockade der Ligandenbindung ebenso wie die spezifische Inhibition der PTK-Aktivität mit niedermolekularen Wirkstoffen oder die Interferenz mit nachgeschalteten Schritten in der Signal-Kaskade. Aktuelle Fortschritte in der Verfolgung einer „Signaltransduktions-Therapie” sollen am Beispiel der Antagonisierung von Rezeptoren der HER/erbB-Familie aufgezeigt werden.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050295
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Last und Lust. Klinik und Forschung beim Ovarialkarzinom (1998)
    Springer
    Der Onkologe 4 (1998), S. 1091-1092 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050299
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...